Fmr LLC Sells 7,224 Shares of Fresenius Medical Care AG (NYSE:FMS)

Fmr LLC lessened its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 8.6% in the third quarter, HoldingsChannel.com reports. The fund owned 76,351 shares of the company’s stock after selling 7,224 shares during the period. Fmr LLC’s holdings in Fresenius Medical Care were worth $1,626,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Wulff Hansen & CO. boosted its position in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares during the last quarter. Moran Wealth Management LLC lifted its position in Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after buying an additional 74,621 shares during the last quarter. Triasima Portfolio Management inc. lifted its position in Fresenius Medical Care by 27.4% in the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after buying an additional 18,360 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after buying an additional 23,692 shares during the last quarter. Finally, Creative Planning lifted its position in Fresenius Medical Care by 18.9% in the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after buying an additional 6,373 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Price Performance

FMS opened at $23.65 on Monday. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $24.31. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $21.51 and a two-hundred day simple moving average of $20.46. The company has a market cap of $13.88 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 0.96 and a beta of 0.94.

Analyst Upgrades and Downgrades

FMS has been the subject of a number of recent research reports. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Berenberg Bank initiated coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. Truist Financial boosted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, StockNews.com assumed coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They issued a “strong-buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.30.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.